The mechanisms that underlie and dictate the different biological outcomes of E2F-1 activity have yet to be elucidated. We describe the residuespecific methylation of E2F-1 by the asymmetric dimethylating protein arginine methyltransferase 1 (PRMT1) and symmetric dimethylating PRMT5 and relate the marks to different functional consequences of E2F-1 activity. Methylation by PRMT1 hinders methylation by PRMT5, which augments E2F-1-dependent apoptosis, whereas PRMT5-dependent methylation favors proliferation by antagonizing methylation by PRMT1. The ability of E2F-1 to prompt apoptosis in DNA damaged cells coincides with enhanced PRMT1 methylation. In contrast, cyclin A binding to E2F-1 impedes PRMT1 methylation and augments PRMT5 methylation, thus ensuring that E2F-1 is locked into its cell-cycle progression mode. The Tudor domain protein p100-TSN reads the symmetric methylation mark, and binding of p100-TSN downregulates E2F-1 apoptotic activity. Our results define an exquisite level of precision in the reader-writer interplay that governs the biological outcome of E2F-1 activity.
INTRODUCTION
The retinoblastoma tumor suppressor protein pRb is a pivotal negative regulator of early cell-cycle progression, mediated in part through its interaction with and control of the E2F family of transcription factors (Frolov and Dyson, 2004) . In tumor cells, either direct mutation in the Rb gene, increased activity of its upstream cyclin/cdk regulators, or through the action of oncoproteins, normal function of pRb is lost, leading to the aberrant control of E2F activity . It is believed that deregulation of the pRb-E2F pathway is a widespread, if not universal, hallmark of cancer cells.
Through its regulation by pRb, the E2F family is inextricably linked to cancer. Since many E2F target genes are connected with cell-cycle progression, it was anticipated that defective pRb control would result in deregulated E2F-dependent transcription and consequential cell-cycle progression (Frolov and Dyson, 2004; . However, as the complexity of the E2F family has become apparent, this viewpoint has been challenged, which is clearly exemplified by studies on the first member of the E2F family, E2F-1. E2F-1 is a direct physical target for pRb, and a large body of evidence supports E2F-1 as a positive regulator of the cell cycle, particularly in activating genes required for S phase progression (Frolov and Dyson, 2004; . In contrast, however, E2F-1 activity is also connected with a role in negatively regulating cell growth and apoptotis (Iaquinta and Lees, 2007; Polager and Ginsberg, 2008; . For example, E2F-1 À/À mice display a phenotype that is more akin to a tumor suppressor role for E2F-1, since the mice are tumor prone and exhibit a heightened incidence of certain tumors, including lung tumors and lymphoma, and conversely atrophy in other tissues like testis (Field et al., 1996; Yamasaki et al., 1996) . In contrast, the progression of pituitary tumors in Rb +/À mice is delayed in an Rb +/À /E2F-1 À/À background, highlighting an oncogenic growth-promoting role for E2F-1 (Iaquinta and Lees, 2007; Yamasaki et al., 1996) . The negative impact of E2F-1 on growth is likely to occur under DNA damage treatment. E2F-1 is DNA damage inducible, and its induction follows similar kinetics to the DNA damage regulation of p53 . This is achieved in part by the action of DNA damage-responsive protein kinases, like ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), and Chk2, which phosphorylate E2F-1, leading to protein stabilization and apoptosis (Stevens and La (legend continued on next page) . The ability of E2F-1 to mediate apoptosis under DNA damage conditions implies a role in checkpoint control, which could in part contribute to its tumor suppressor activity. An important question that relates to the biology of E2F-1 concerns the mechanisms that control its opposing functional roles in proliferation and apoptosis, often referred to as the ''yin-yang'' of E2F-1 (La Polager and Ginsberg, 2008) . Little information is available on the molecular mechanisms that control the opposing outcomes of E2F-1 activity. However, in previous studies a small arginine-rich motif in E2F-1, which shares considerable sequence homology with a similar motif in p53 (Cho et al., 2012; Jansson et al., 2008) , was shown to undergo symmetrical methylation by the protein arginine methyl transferase (PRMT5). This modification impinges on the functional properties of E2F-1, most significantly apoptosis (Cho et al., 2012) .
Here, we describe results that delineate reader-writer interplay on E2F-1 mediated through distinct types of arginine methylation mark. Remarkably, the arginine-rich motif is competitively methylated by different PRMTs, notably PRMT1 and PRMT5, resulting in residue-and methylation-specific marks. Methylation by PRMT1 holds E2F-1 in an apoptotic mode, as opposed to methylation by PRMT5, which facilitates cell-cycle progression. DNA damage augments the PRMT1 mark, whereas cyclin A binding to E2F-1 favors methylation by PRMT5. Significantly, the Tudor domain protein p100-TSN reads the symmetric methylation mark on E2F-1, and the interaction between p100-TSN and E2F-1 alters its biochemical properties, limits apoptosis, and fosters cell-cycle progression. Our results define a readerwriter interplay determined by arginine methylation marks, which controls E2F-1 switching between apoptosis and cell-cycle progression and thus governs growth control by E2F-1.
RESULTS

E2F-1 Undergoes Arginine Methylation by PRMT1 and PRMT5
PRMT5 symmetrically methylates E2F-1 on arginine (R) residues 111 and 113 (Cho et al., 2012) . We evaluated whether asymmetric arginine methylation also occurred on E2F-1 by immunoprecipitating endogenous E2F-1 followed by immunoblotting with antiasymmetric and antisymmetric methylation-specific antibodies; both modifications were detected on E2F-1 and absent when cells were treated with E2F-1 siRNA before the immunoprecipitation step ( Figure 1A) . Moreover, when the E2F-1 immunocomplex was assessed for symmetrically acting PRMTs, an interaction was detected between E2F-1 and PRMT1 in addition to PRMT5 ( Figure 1B) . The asymmetric arginine methylation mark on E2F-1 was dependent on PRMT1 because it was no longer detectable on E2F-1 immunoprecipitated from PRMT1 siRNA-treated cells ( Figure 1C) ; a similar effect was apparent on the symmetrical methylation modification of E2F-1 in cells treated with PRMT5 siRNA ( Figure 1C ). Furthermore, PRMT1 was able to methylate E2F-1 in vitro, as PRMT1 immunopurified from cells (with undetectable PRMT5) was capable of methylating E2F-1 in vitro (Figure S1A available online). Ectopic PRMT5 behaved in a similar fashion, as immunopurified PRMT5 (with undetectable PRMT1) could methylate E2F-1 in vitro ( Figure S1B ). These results were recapitulated with recombinant proteins, as both GST-PRMT1 and GST-PRMT5 methylated E2F-1 in vitro (data not shown). Thus, interactions between E2F-1 and PRMT1 and E2F-1 and PRMT5 reflected the presence of the relevant arginine methylation mark on E2F-1 in cells, namely asymmetric (by PRMT1) or symmetric (by PRMT5), respectively.
We investigated the residues in E2F-1 methylated by PRMT1 by using a panel of single-residue substitutions expressed as glutathione S-transferase (GST)-E2F-1 fusion proteins (R to K; Figure 1D ). Each purified GST-E2F-1 fusion protein was incubated with either ectopic PRMT1 or PRMT5, and their capacities as methylation substrates were measured. As expected, wildtype GST-E2F-1 could be methylated in vitro by PRMT1 and PRMT5 (Figures 1E and 1F) . Substitution at either R111 or R113 (single or in combination) failed to alter the methylation of E2F-1 by PRMT1, in contrast to mutating R109, as the R109K mutant was poorly methylated by PRMT1 ( Figures 1E and 1F ). In contrast, PRMT5 efficiently methylated R109K but failed to (B) Lysate from SAOS2 cells was immunoprecipitated with control IgG (cont), E2F-1, PRMT1, or PRMT5 antibodies and subsequently immunoblotted with the indicated antibodies. Input (In) levels of the respective proteins are shown. (C) SAOS2 cells were transfected with nontargeting control (NC), PRMT1 (P1), PRMT5 (P5), or E2F-1 (E) siRNA (50 nM). Cell lysates were immunoprecipitated with control IgG (cont) or E2F-1 antibodies and subsequently immunoblotted with the indicated antibodies. Input (In) levels of the respective proteins are shown, and actin provides a loading control. See also Figure S5 . (D) Organization of E2F-1, highlighting cyclin A binding domain (CyA), DNA binding/DP subunit dimerization domain, transcription activation domain (TAD) and pRb binding (pRb), and the arginine-rich motif. Arginine residues in E2F-1 are highlighted in orange. Substitutions of arginine (R) to lysine (K) were created in GST-E2F-1 at R109, R111, and R113, highlighted in blue. (E) Either HA-PRMT1 or Flag-PRMT5 was incubated with GST-E2F1 (1 mg) protein derivatives in methylation assays with 3 H-SAM as cosubstrate. Incorporation of 3 H-methyl groups was detected by autoradiography (indicated as autorad). The identity of methylated protein was confirmed by immunoblotting with E2F-1 antibodies (IB: E2F-1). Ponceau staining was used as a loading control for input E2F-1 levels. See also Figure S1 . (F) Either HA-PRMT1 or Flag-PRMT5 was incubated with GST-E2F-1 as indicated (1 mg) (negative control in white, HA-PRMT1 in gray, and Flag-PRMT5 in black). The GST tag, enzymes, or substrate alone were used as negative controls, where (À) represents the absence of substrate. The data show the mean of three independent experiments, with error bars representing SD; *p < 0.05; NS, no statistically significant difference. (G) Lysates from cells transfected with wild-type (WT) E2F-1 and the indicated mutant derivatives were immunoprecipitated using control IgG or HA antibodies, followed by immunoblotting with E2F-1, ADMA, or SDMA antibodies as indicated. E2F-1 protein input levels (In) are shown, and actin levels provide the loading control. See also Figure S4 . Figure 1G ). However, the R109K mutant had readily detectable levels of symmetric methylation (SDMA; Figure 1G ). An analysis by tandem mass spectrometry of E2F-1 purified from cells provided further support for dimethylation at R109 ( Figure S4 ). These results therefore establish that R109 is the major site of asymmetric arginine methylation on E2F-1 in cells and identify PRMT1 as the enzyme responsible for the methylation event.
Competition between PRMT1 and PRMT5 for E2F-1 Methylation Since PRMT1 and PRMT5 bind to and methylate a similar region in E2F-1 ( Figure 1D ), we reasoned that competition between the two enzymes may occur. We tested this idea by immunoprecipitating E2F-1 from cells treated with either PRMT1 or PRMT5 siRNA, and we measured the interaction between E2F-1 and the other PRMT enzyme. The interaction between E2F-1 and PRMT5 was enhanced when PRMT1 was depleted, and conversely, the interaction between PRMT1 and E2F-1 increased in conditions of PRMT5 depletion ( Figure 1C) . Significantly, the level of E2F-1 methylation coincided with PRMT binding. Thus, enhanced PRMT1 binding under PRMT5 siRNA treatment conditions reflected increased E2F-1 asymmetric arginine methylation, and conversely, enhanced levels of PRMT5 upon PRMT1 siRNA treatment reflected greater symmetric methylation (Figure 1C) . Further, ectopic PRMT1 expression in a stable cell line caused an enhanced asymmetric and decreased symmetric mark on E2F-1 ( Figure S5A ). We next examined whether the methylation mark mediated by each enzyme was able to interfere with methylation by the other enzyme. We used chemically synthesized E2F-1 peptides in which individual arginine residues within the R-rich motif were either asymmetrically or symmetrically modified to reflect the methylation mark in cells ( Figure 1H) . A peptide in which each R residue had been changed to a K residue, KKK, could not be methylated by either PRMT1 or PRMT5 ( Figure 1H ). PRMT1 methylated the E2F-1 peptide only when R109 was in the unmodified state, since the asymmetrically methylated R109 (R109-ADMA) peptide was poorly methylated ( Figure 1H ). Similarly, PRMT5 methylated the E2F-1 peptide, but not when the peptide had symmetric methylation at R111 and R113 (R111/ R113-SDMA; Figure 1H ). Interestingly, R111/R113-SDMA had an impact on R109 methylation by PRMT1, as methylation by PRMT1 of R111/R113-SDMA was reduced when compared to the unmodified E2F-1 peptide, and R109-ADMA affected the methylation of R111 and R113 by PRMT5, as PRMT5 methylation of R111/R113-SDMA was also reduced ( Figure 1H ). These results define a biochemical antagonism between the methylation events on E2F-1 carried out by PRMT1 and PRMT5.
We established that the methylated peptide results were relevant to what happens in cells by studying the properties of the E2F-1 mutant derivatives. The R109K mutant had reduced levels of asymmetric methylation but exhibited higher levels of symmetric methylation compared to wild-type E2F-1 ( Figure 1G ). Conversely, mutation of R111 or R113 resulted in reduced symmetric methylation and a corresponding increased level of asymmetric modification compared to wild-type E2F-1 ( Figure 1G ). Combined with the methylated peptide results ( Figure 1H ), these results are consistent with the idea that methylation by PRMT1 or PRMT5 impacts methylation by the other PRMT enzyme; namely, methylated R109 hinders symmetric methylation at R111 and R113, and methylation of R111 and R113 reduces asymmetric methylation at R109.
We were interested in studying the role of PRMT1 methylation of E2F-1 and identify any biochemical differences that might occur through the arginine residues targeted by each enzyme. We therefore compared the half-life of R109K to wild-type E2F-1, R111/113K, and KKK. The R109K mutant had a much shorter half-life compared to wild-type E2F-1, and an even greater difference in half-life was apparent when R109K was compared to R111/113K (1 hr compared to 6 hr; Figures 2A-2C). In cells treated with PRMT1 siRNA ( Figure 2D ), E2F-1 had a shorter half-life than wild-type E2F-1, and an extended halflife was observed in cells depleted of PRMT5 , which is consistent with the stability differences apparent with the R-to-K mutants. Therefore, opposite biochemical consequences occur upon asymmetric and symmetric arginine methylation of E2F-1, as PRMT1 methylation increases E2F-1 half-life, in contrast to PRMT5 methylation, which reduces E2F-1 half-life.
Impact of E2F-1 Methylation on Chromatin Binding and Transcription
We further investigated whether there were any differences regarding the effects of PRMT1 and PRMT5 on E2F-1 promoter binding activity by chromatin immunoprecipitation (ChIP), using a selection of E2F target genes connected with different cell fates ( Figure S2 ). PRMT1 depletion led to reduced E2F-1 ChIP activity across the set of genes examined, contrasting with PRMT5 depletion, where enhanced ChIP activity was apparent ( Figure S2 ; Cho et al., 2012) . To establish that the differences in promoter binding did not only result from the altered level and half-life of E2F-1 protein caused by manipulating PRMT1 and PRMT5, we evaluated the properties of individual E2F-1 mutant derivatives under conditions of equivalent protein expression ( Figure S2 ). The R109K mutant exhibited reduced ChIP activity relative to wild-type E2F-1, contrasting with mutation of R111 or R113, or both together, where enhanced E2F-1 ChIP activity was evident ( Figure S2 ). Under conditions of either combined PRMT1 and PRTM5 siRNA treatment or expression of the KKK mutant, it was R111 and R113 that provided the dominant effect ( Figure S2 ). These results highlight the opposing effects of PRMT1 and PRMT5 on E2F-1 chromatin binding activity. We investigated the influence of PRMT1 and PRMT5 on the transcriptional activity of E2F target genes using a panel of luciferase reporters ( Figure S3 ). Depleting PRMT1 with siRNA caused reduced transcriptional activity relative to the control siRNAtreated cells ( Figure S3 ). In contrast, PRMT5 siRNA resulted in an increase in transcription ( Figure S3 ; Cho et al., 2012) . In conditions of the combined depletion of PRMT1 and PRMT5, enhanced levels of transcription were retained ( Figure S3 ). The transcription properties of the E2F-1 mutants were also assessed where, at equivalent levels, the activity of the R109K was compromised compared to wild-type E2F-1 ( Figure S3 ). In contrast, mutating either R111, R113, or both residues together resulted in enhanced activity ( Figure S3 ). Thus, asymmetric and symmetric arginine methylation have opposite effects on E2F-1 activity.
In order to determine the influence of PRMT1 and PRMT5 on endogenous E2F target genes, we measured RNA levels in siRNA-treated cells ( Figures 2H and S1C ). Depleting PRMT1 reduced the expression of a variety of E2F target genes, with , and/or PRMT5 (P5; 50 nM) and harvested after 48 hr. Cell lysates were immunoblotted with the indicated antibodies to assess relative protein levels. Actin was used as a loading control. (E) Cycloheximide (100 ng/ml) was added to cells treated under the same conditions as described in (A) and harvested at 0, 2, 4, 6, and 8 hr posttreatment time points. Cell lysates were immunoblotted with antibodies against E2F-1. Actin was used as a loading control.
(F) Quantitation of E2F-1 protein levels (E) shown as the percentage of change relative to cycloheximide pretreatment.
(G) E2F-1 protein half-life calculated from the data in (E) . Data from three independent experiments are represented as mean ± SEM. (H) SAOS2 cells were treated with nontargeting control (NC), PRMT1 (P1), and/or PRMT5 (P5; 50 nM) and harvested after 48 hr. RNA levels were assessed by PCR. 18S rRNA and GAPDH mRNA were used as controls (i). The percentage of change in RNA levels relative to nontargeting siRNA control treatment is shown. 18S rRNA was used as the control (ii). Data from three independent experiments are represented as mean ± SEM. the greatest effect apparent on genes such as APAF1, E2F-1, and p73, contrasting with PRMT5 depletion, which caused an increase in the RNA level of the same genes ( Figure 2H ). The combined depletion of PRMT1 and PRMT5 retained the increased expression profile characteristic of PRMT5 siRNA alone ( Figure 2H ). Thus, PRMT1 is a positive regulator of some E2F-1 target genes, in contrast to PRMT5, which is a negative regulator. Furthermore, genes connected with apoptosis (p73, APAF1, and E2F-1) are particularly sensitive to control by arginine-methylated E2F-1.
Arginine Methylation in E2F-1-Dependent Growth Control
We assessed the role of PRMT1 in regulating cell growth in a colony formation assay, where PRMT1 depletion resulted in an increased growth rate compared to the control treatment (Figures 3A , S5B, and S5C). The increased growth was dependent on E2F-1 because it was lost when PRMT1 and E2F-1 were depleted together ( Figure 3A ). This was also apparent when viable cells were quantitated by measuring cellular ATP (as a measure of metabolically active cells), where cell number increased upon PRMT1 depletion relative to the control siRNA treatment, and this effect was again reduced when E2F-1 was codepleted ( Figure 3B ). The influence of PRMT1 on cell growth was in sharp contrast to PRMT5, where growth inhibition was apparent again in a fashion dependent upon E2F-1 activity (Figure 3B ; Cho et al., 2012) . In cells depleted of both PRMT1 and PRMT5, growth inhibition was apparent, which again was mediated through E2F-1 ( Figures 3A and 3B ). The growth-regulating properties of the E2F-1 mutants were assessed in similar assays. R109K caused less growth inhibition than wild-type E2F-1, which was even more striking when R109K was compared to R111/R113K, where enhanced growth inhibition was evident ( Figure 3C ). Similar outcomes were evident when cellular ATP was measured, which again verified the significant growth advantage of R109K relative to wild-type E2F-1 and growth inhibition by the R111/113K mutant ( Figure 3D) . We continued the analysis of PRMT1 and PRMT5 by measuring apoptosis, specifically the level of cleaved PARP and sub-G1 cells (Figures 3E and 3F ). PRMT1 siRNA reduced the level of apoptotic (sub-G1) cells, contrasting with PRMT5 siRNA, where a greater level of apoptosis was evident and both effects of PRMT1 and PRMT5 were dependent upon E2F-1 ( Figure 3E) . Similarly, opposite effects of PRMT1 and PRMT5 siRNA were apparent on PARP cleavage, as PRMT1 siRNA caused a modest decrease contrasting with PRMT5 siRNA where an increased level of cleaved PARP was apparent ( Figure 3F ). Altogether, these results establish opposite roles for asymmetric and symmetric methylation marks on E2F-1 in regulating cell growth and apoptosis.
Regulation of Arginine Methylation under DNA Damage Conditions E2F-1 is a DNA damage-responsive protein and drives apoptosis in DNA damaged cells Polager and Ginsberg, 2008; . We were interested in establishing the role of PRMT1 and PRMT5 in E2F-1 control under DNA damage conditions. In cells treated with etoposide, the level of E2F-1 increased ( Figure 4A ). Under these DNA damage conditions, PRMT1 siRNA reduced the level of E2F-1, which coincided with decreased PARP cleavage and sub-G1 cells compared to the control siRNA treatment ( Figures 4A and 4B ). In contrast, PRMT5 siRNA enhanced the level of E2F-1, which reflected increased PARP cleavage and sub-G1 cells (Figures 4A and 4B; Cho et al., 2012) .
Both asymmetric and symmetric arginine methylation modifications occur on E2F-1 in unperturbed cells ( Figures 1A and  1C) . In DNA damaged cells (treated with either doxorubicin or etoposide), the enhanced level of E2F-1 coincided with decreased interaction with PRMT5 and a corresponding reduction in symmetric arginine methylation ( Figure 4C ; SDMA). In contrast, an enhanced interaction with PRMT1 and an associated increase in asymmetric arginine methylation occurred (Figure 4C ; ADMA), and the greater methylation by PRMT1 and reduced methylation by PRMT5 reflected increased E2F-1 levels and expression of E2F target genes ( Figure S1D ). Thus, arginine methylation of E2F-1 mediated by PRMT1 and PRMT5 is regulated by DNA damage. The competitive binding events between PRMT1 and PRMT5 noted earlier (Figure 1 ) might contribute to the regulated methylated events.
We then investigated the effect of PRMT1 on E2F-1 under DNA damage conditions in colony formation assays. As expected, fewer colonies were evident in etoposide-treated cells compared to unperturbed cells, and inhibition of colony formation controls (NC) are represented by white bars, and E2F-1 codepletion (siE) is represented by black bars (ii). The data are from three independent experiments (mean ± SEM) and represent the change in cell density relative to nontargeting (NC) siRNA control treatment. (B) ATP luminescence assay representing viable cells upon PRMT1 and/or PRMT5 depletion (i, ii, and iii). SAOS2 cells were treated with the indicated siRNA, as previously described, and subjected to fluorometric ATP assay at 48, 72, 96, and 120 hr posttreatment time points. Data from three independent experiments are represented as mean ± SEM. Cell lysates were probed with the indicated antibodies to assess relative protein levels (iv). Actin was used as a loading control. (C) SAOS2 cells were seeded at low density in 6-well plates (2,000 cells per well) and transfected with empty vector control (-) or HA-E2F-1 plasmids ($1 mg) as previously described. The cells were harvested after 7 or 10 days posttransfection and stained with crystal violet dye (i). Cell density of the above images relative to empty vector control treatment. Quantitation was performed by ImageJ. Data from three independent experiments are represented as mean ± SEM (ii). (D) ATP luminescence results representing a viable SAOS2 cell assay in which cells expressed the E2F-1 mutant derivatives (i). Data from three independent experiments are represented as mean ± SEM. Cell lysates were probed with HA antibody to assess transfected E2F-1 protein levels (ii). Actin was used as a loading control. (E) SAOS2 cells were treated with the indicated siRNA, as described, and harvested at 72 hr posttransfection for flow cytometry. Nontargeting control (NC) is represented by black bars and E2F-1 codepletion by white bars. Data from three independent experiments are represented as mean ± SEM; *p < 0.05; NS, no statistically significant difference. (F) SAOS2 cells were treated with nontargeting (NC), E2F-1 (E), PRMT1 (P1), or PRMT5 (P5) siRNA (50 nM) and harvested after 48 hr, followed by immunoblotting with the indicated antibodies. (A) SAOS2 cells were treated as shown with the siRNAs indicated (50 nM) and at 24 hr with etoposide (10 mM for 48 hr), and lysates were probed with the indicated antibodies by immunoblotting. Actin was used as the loading control. (B) SAOS2 cells were treated with the indicated siRNAs (as in A) and harvested at 48 hr for flow cytometry analysis. DMSO control (cont) is indicated by white bars, and etoposide treatment is indicated by black bars. Data show the sub-G1 fraction of cells from three independent experiments represented as the mean ± SEM; *p < 0.05; NS, no statistically significant difference. (C) SAOS2 cells were treated with doxorubicin (2 mM), etoposide (10 mM), or an equivalent volume of DMSO solvent (-) for 48 hr. Cell lysates were immunoprecipitated with control IgG or E2F-1 antibodies and immunoblotted with the indicated antibodies. Input levels of the respective proteins are shown. (D) SAOS2 cells were seeded at low density in 6-well plates (1,000 cells per well) and treated with the indicated siRNA as described. At 24 hr posttransfection, the cells were treated with etoposide (10 mM) or an equivalent volume of DMSO solvent (cont). After 10 days, the cells were harvested and stained with crystal violet dye (i). Cell density of the above images relative to NC siRNA control treatment (ii). Data from three independent experiments are represented as mean ± SEM. (E) Colony assay was performed as described in SAOS2 cells (1,000 cells/well) treated with the indicated siRNAs together with etoposide (10 mM). Cells were harvested and stained with crystal violet at 10 days (i). Cell lysates prepared from the same cells were immunoblotted with the indicated antibodies (ii). Quantification relative to NC siRNA control was performed as described (iii). Data from three independent experiments are represented as mean ± SEM.
was enhanced upon treatment with PRMT5 siRNA ( Figure 4D) . Remarkably, however, PRMT1 siRNA enhanced colony formation activity and overcame the growth inhibitory activity of etoposide relative to the control siRNA treatment ( Figure 4D ). The enhanced colony formation apparent upon PRMT1 siRNA treatment and the reduced colony formation upon PRMT5 siRNA cotreatment were dependent on E2F-1 activity ( Figure 4E ). However, the ability of PRMT1 siRNA to overcome DNA damageinduced growth inhibition was lost upon codepletion with PRMT5 ( Figures 4D and 4E) , arguing that the colony formation activity seen under PRMT1 siRNA treatment was mediated through PRMT5 and symmetric methylation of R111 and R113. The enhanced symmetrical arginine methylation and increased PRMT5 binding upon PRMT1 depletion ( Figure 1C) is consistent with the observed increase in colony activity under DNA damage from PRMT1 siRNA, as PRMT5-dependent symmetric modification of E2F-1 would be expected to suppress its apoptotic activity.
Arginine Methylation and Cyclin A Binding to E2F-1
The cyclin A/cdk2 binding motif in E2F-1 is located in the region from residue 87 to 95, containing the core consensus cyclin binding motif RRL (Adams et al., 1996) . We reasoned that the juxtaposition of this motif with the R-rich motif might result in a level of competitive interplay between cyclin A and PRMT1 and/or PRMT5. We tested this idea by treating cells with cyclin A siRNA and monitoring the effect on E2F-1 methylation and interaction with PRMT1 and PRMT5. An interaction was apparent between E2F-1 and cyclin A, and PRMT5 could be detected in the same immunoprecipitated complex ( Figure 5A ). In cells treated with cyclin A siRNA, increased levels of E2F-1 occurred, with a concomitant increase in the level of PRMT1 and reduced PRMT5 in the E2F-1 immunocomplex ( Figure 5A ). Furthermore, changes in the level of arginine methylation mirrored these binding events, as asymmetric arginine methylation of E2F-1 was higher in cyclin A siRNA-treated cells in contrast to symmetric arginine methylation, which was highest in the control siRNA-treated cells ( Figure 5A ). The absence of cyclin A binding to E2F-1 therefore enabled enhanced PRMT1 and reduced PRMT5 interaction, which thus resemble the profile of interaction and methylation events that occur in DNA damaged cells ( Figure 4C ).
When the interaction between E2F-1 and cyclin A was examined in DNA damaged cells, a decreased interaction with cyclin A was observed compared to undamaged cells ( Figure 5B ). Moreover, the decreased cyclin A binding in DNA damaged cells coincided with enhanced PRMT1 and reduced PRMT5 binding to E2F-1, together with enhanced asymmetric and reduced symmetric, respectively ( Figure 5B) . Thus, cyclin A binding hinders PRMT1, which favors PRMT5 interacting with E2F-1, and DNA damage causes a decreased interaction with cyclin A, which allows a stronger interaction with PRMT1, with reduced PRMT5 binding.
The increased binding of PRMT1 to E2F-1 under conditions of decreased cyclin A binding and the coincidental increase in asymmetric methylation would, based on the earlier results, be expected to facilitate E2F-1-dependent apoptosis (by virtue of PRMT1 methylation hindering PRMT5 methylation; Figure 1C ).
We tested this idea using a cyclin A binding-defective E2F-1 derivative in which the cyclin A binding domain had been removed (D87-95; Figure 5C ). The E2F-1D87-95 mutant exhibited an enhanced interaction with PRMT1 and reduced PRMT5 interaction as well as an associated increase in asymmetric, but not symmetric, methylation ( Figure 5C ). Significantly, E2F-1D87-95 reduced colony formation (under normal and DNA damage conditions) more effectively than wild-type E2F-1, similar to the level seen with the R111/113K mutant ( Figure 5D ), and D87-95 displayed increased apoptotic activity relative to wild-type E2F-1 according to flow cytometry ( Figure S1E) . Thus, cyclin A binding to E2F-1 has an impact on the type of arginine methylation mark that occurs on E2F-1, which thereby controls cell-cycle progression by E2F-1 activity.
p100-TSN Reads E2F-1 Arginine Methylation
Because the methylation status of R111/R113 impacts E2F-1-dependent apoptosis, and since the effect of R109 methylation is mediated in part through the regulation of the methylation status of R111/R113, it was important to gather an understanding of proteins that read the symmetrical arginine methylation mark. We prepared biotinylated E2F-1 peptides that were either unmodified or symmetrically modified (SDMA) at R111 and R113 and used the fluorescently labeled streptavidin conjugate to screen the chromatin-associated domain array (CADOR; Kim et al., 2006; Yang et al., 2010) . CADOR is a protein array platform developed to identify protein domains that bind to modified peptides and includes the vast majority of reader domains involved with chromatin and transcriptional control (Yang et al., 2010) . We identified a single hit in the screen, p100-TSN (TDRD11), which bound only to R111/113 SDMA peptide and not the unmethylated E2F-1 peptide ( Figure 6A ). p100-TSN is composed of a single extended Tudor domain (TD) and five staphylococcal nuclease (SN)-like domains ( Figure 6B ) (Shaw et al., 2007) . The Tudor domain is a member of the Royal family of protein domains that bind to methyllysine and methylarginine residues (Chen et al., 2011) , and p100-TSN has documented roles in RNA processing and transcriptional regulation (Shaw et al., 2007; Vä lineva et al., 2005) .
We established that the interaction between p100-TSN and E2F-1 was arginine methylation dependent using in vitro and cell-based approaches. In a peptide binding assay, only R111/ 113 SDMA and not the unmethylated or R109 ADMA E2F-1 peptide bound to p100-TSN ( Figures 6C and S1F) , confirming the specificity of p100-TSN for symmetric arginine methylation. A kinetic biophysical analysis by biolayer interferometry of the binding between the p100-TSN Tudor domain and R111/113 SDMA peptide determined the dissociation constant (KD) to be in the order of 12 mM ( Figure 6D ), which is similar to the KD for other reader domains of arginine methylation marks (Liu et al., 2010) ; there was no detectable binding to the unmodified peptide. Moreover, the integrity of the Tudor domain in p100-TSN was required for the interaction because the Tudor domain-inactivating mutant E770K failed to bind to the R111/113 SDMA peptide ( Figure 6C ), which is consistent with the role of the Tudor domain in recognizing methylated arginine residues (Liu et al., 2010) . In both unperturbed and transfected cells, an interaction was apparent between E2F-1 and p100-TSN ( Figures 6E, 6F, and 6H). The interaction was dependent on symmetric arginine methylation because p100-TSN failed to interact with the R111/113K mutant, contrasting with wild-type E2F-1 (Figure 6F) , and the interaction between E2F-1 and p100-TSN was enhanced by the ectopic expression of PRMT5 ( Figure 6G ) and reduced upon PRMT5 siRNA treatment ( Figure 6H ). Furthermore, the interaction between p100-TSN and E2F-1 affected the half-life of E2F-1. Thus, an extended half-life was apparent (legend continued on next page)
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Arginine Methylation Regulates E2F-1 Biology in p100-TSN siRNA-treated cells, which resembled the effect of PRMT5 siRNA on E2F-1 half-life ( Figures 6I-6L ). In cells treated with both p100-TSN and PRMT5 siRNA, E2F-1 half-life remained similar to the single siRNA treatments ( Figure 6L ), suggesting that p100-TSN is involved in mediating the effect of the SDMA mark on E2F-1. The ability of p100-TSN to bind to the form of E2F-1 that has reduced apoptotic activity (namely R111/113 SDMA) suggested that, in cells, the interaction could influence cell viability. We tested this idea by depleting p100-TSN with siRNA, which resulted in increased levels of E2F-1 and an associated increase in PARP cleavage ( Figure 7A ). Significantly, codepletion of p100-TSN and E2F-1 overcame PARP cleavage ( Figure 7A ), indicating that the effect of p100-TSN on apoptosis was mediated through E2F-1. A similar relationship between p100-TSN and E2F-1 was evident when sub-G1 cells were measured by flow cytometry ( Figure 7B ). Further, in a colony formation assay p100-TSN siRNA decreased colony formation, which was no longer apparent when p100-TSN and E2F-1 were codepleted ( Figure 7C ).
To resolve the mechanism involved in greater detail, we addressed whether p100-TSN could bind to the promoters of E2F target genes. By ChIP, p100-TSN was detected on E2F-1, cyclin E, Cdc6, and DHFR genes, contrasting with the APAF-1 and p73 genes, in which p100-TSN was not detectable (Figure 7D) . The presence of p100-TSN on E2F target genes was dependent on E2F-1, since p100-TSN ChIP activity was lost in E2F-1-siRNA treated cells ( Figure 7D ). Similarly, p100-TSN ChIP activity was absent in PRMT5 siRNA-treated cells (Figure 7D) . Furthermore, enhanced p100-TSN ChIP activity was apparent in PRMT1 siRNA-treated cells ( Figure 7D ), which is compatible with the enhanced SDMA mark on E2F-1 upon PRMT1 siRNA treatment ( Figure 1C ) and recognition of SDMA by p100-TSN ( Figure 6C ). These results indicate that p100-TSN reads the SDMA mark on E2F-1 and further suggest that the interaction regulates cell viability. This occurs, in part, through p100-TSN regulating E2F-1 stability and targeting a group of E2F-responsive genes.
DISCUSSION
Our results highlight an exquisite level of precision, mediated through residue-and modification-specific arginine methylation, which regulates the biological activity of E2F-1. Thus, asymmetric arginine methylation by PRMT1 (at R109) causes growth inhibition and apoptosis, contrasting with symmetrical methylation by PRMT5 (at R111 and R113), which favors proliferation. These modifications reflect changes in the expression of E2F target genes; PRMT1 methylation augments the expression genes connected with apoptosis, whereas PRMT5 methylation suppresses their expression level. Moreover, an important level of crosstalk and interplay occurs between the two types of marks, as each is able to interfere with subsequent modification by the other enzyme, and the effect of PRMT1 on E2F-1 appears to be mediated in part through the regulation of PRMT5-mediated methylation events.
DNA damage is believed to activate the apoptotic properties of E2F-1 (Polager and Ginsberg, 2008; . Analyzing arginine methylation in DNA damaged cells indicated that increased levels of asymmetric arginine methylation occurred, with the coincident inhibition of PRMT5 binding and symmetric arginine methylation. Accordingly, reduced methylation at R111 and R113, as a consequence of interference from R109 methylation, would be expected and was seen to augment E2F-1-dependent apoptosis. Conversely, methylation at R111 and R113, and the concomitant reduced methylation at R109, enhanced cell viability, in part by inhibiting the apoptosis that results from unmethylated R111 and R113 (Figure 7E) . These results therefore provide a mechanism relying on arginine methylation that explains how the different biological outputs ascribed to E2F-1 can be regulated.
Our results uncovered a role for cyclin A binding in regulating E2F-1 arginine methylation. Cyclin A interacts with E2F-1 through a well-defined peptide motif (Adams et al., 1996) , although the significance of this interaction remains largely unknown (Malumbres and Barbacid, 2009 ). We found that cyclin A binding to E2F-1 hinders PRMT1 binding, thereby facilitating (legend continued on next page)
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Arginine Methylation Regulates E2F-1 Biology PRMT5-dependent methylation, which is able to hold cells in the proliferative cycle by overcoming apoptosis driven by E2F-1. Cyclin A binding therefore regulates the ability of E2F-1 to drive apoptosis or promote proliferation by influencing the type of methylation mark that occurs on E2F-1 ( Figure 7E ). It is consistent with this idea that peptides that block the cyclin A/cdk2 interaction with E2F-1 promote apoptosis (Chen et al., 1999) . Most significantly, the symmetric arginine methylation mark mediated by PRMT5 is read by the Tudor domain protein p100-TSN (Chen et al., 2011) , which suppresses E2F-1-dependent apoptosis. Because p100-TSN binds only to methylated E2F-1, the binding event provides a mechanism by which to switch the biological activity of E2F-1 from apoptosis to proliferation in an arginine methylation-dependent fashion ( Figure 7E ). Further, p100-TSN was present on the promoter of a group of E2F target genes, mostly concerned with proliferation control. The interaction could be highly relevant to oncogenesis, as p100-TSN expression is associated with cancer and inhibits apoptosis (Blanco et al., 2011) , and PRMT5 is under aberrant control and highly expressed in a variety of human tumors (Karkhanis et al., 2011) .
In conclusion, we have established a level of reader-writer interplay that acts as a critical step in dictating the biological outcome of E2F-1 activity. Perturbations in the cellular level of PRMT1 and PRMT5, and the consequent impact on methylation marks and their reading by Tudor domains, might be expected to affect the function of E2F-1, directing its cellular role to either proliferation or apoptosis. Thus, our results provide a plausible explanation for the biological control of E2F-1 activity.
